MondaySep 26, 2022 10:30 am

Cepton, Inc. (NASDAQ: CPTN) Receives Letter of Intent for Up to $100 Million Investment from Strategic Investor; Lidar Technology’s Total Addressable Market Projected to Expand Exponentially

Cepton received a letter of intent from Koito for an investment of up to $100 million to help fund Cepton’s next stage of growth as it scales for mass market deploymentLidar technology within urban settings is becoming increasingly ubiquitous across automotive (i.e., assisted driving & autonomous vehicles) and smart infrastructureSince being the recipient of the largest known ADAS contract from an automotive manufacturer within the lidar space, Cepton maintains a major frontrunner Cepton’s (NASDAQ: CPTN) long-term automotive Tier 1 partner, Koito Manufacturing Co., Ltd. recently revealed that it had provided Cepton with a Letter of Intent representing an investment of…

Continue Reading

WednesdaySep 21, 2022 12:45 pm

Flora Growth Corp. (NASDAQ: FLGC) 7x YOY Revenue Growth for H1 2022 Affirms Hyper Growth

H1 2022 revenue increased to ~$15.0 million, up 604% from H1 2021 and 117% from H2 2021, driven by House of BrandsGross Profit increased to ~$7.0 million, up 547% compared to H1 2021 and 363% compared to H2 2021Company reaffirms its 2022 revenue guidance to range between $35.0 million - $45.0 million, indicating approximately 300% - 400% projected revenue growth from 2021 In August, Flora (NASDAQ: FLGC) released its financial and operating results for the six months that ended June 30, 2022 (https://ibn.fm/NjsJi). As an internationally focused cannabis company, the organization’s management acknowledged how challenging the current global cannabis environment…

Continue Reading

WednesdaySep 21, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Provide Bioavailable Oral Treatment for Hypertension, Mitigate Effects of High Blood Pressure

Lexaria is a biotechnology company pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”)The company has developed the patented DehydraTECH(TM) drug delivery technology, which has been shown to deliver more API at a faster rate than controlsLexaria’s DehydraTECH pipeline includes DehydraTECH-CBD for the treatment of hypertensionThrough pre-clinical studies, DehydraTECH-CBD has been shown to decrease systolic blood pressure among hypertensive volunteersThe company intends to file an Investigational New Drug (“IND”) application and has already received confirmation that the FDA agrees with its proposed abbreviated pathway under section 501(b)(2) Oral delivery remains the preferred…

Continue Reading

TuesdaySep 20, 2022 1:30 pm

Freight Technologies Inc. (NASDAQ: FRGT) Using Technology to Help Customers Overcome Challenges of Cross-Border Logistics, Greatly Improving Efficiency

Freight Technologies is a technology company that develops solutions aimed at optimizing and automating the supply chain processThe company’s solutions include Fr8App Platform, Fr8FMS, cloud-based Fr8TMS, Fr8Radar, Fr8Data, and Fr8FleetEarly this year, Freight Technologies unveiled Fr8Fleet, a technology solution for committed capacity planning, and announced it had secured its first contract for this product with Kimberly Clark de Mexico (“KCM”)The company recently reported an expanded relationship with KCM following an agreement to include the Fr8App platform for cross-border logistics for shipments from Mexico to the U.S. An insights report by multinational KPMG, entitled “The challenges of cross-border international trade,” lists…

Continue Reading

TuesdaySep 20, 2022 12:45 pm

Flora Growth Corp. (NASDAQ: FLGC) Agreement with Colombian Tribe Strengthens Cannabis Production Supply Chain

Flora Growth is a global cannabis brand-builder focused on the cultivation of product at a central Colombian facility and marketing through a design-led international supply chainFlora recently announced an agreement with Colombia’s Misak tribe for cooperative processing and distribution of cannabis, drawing on the tribe’s licensing advantage to accelerate the pair’s marketing capacityFlora is headquartered in Canada, but its strength lies in its Colombian-based cultivation operations centered in Colombia, one of the largest licensed outdoor operations in the worldIn recent years, Colombia’s government has been working to create a legalization framework for cannabis cultivation, processing and exportation to shake off…

Continue Reading

TuesdaySep 20, 2022 12:00 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Clinical Trial Marks ‘Tremendous’ Milestone as First Participants Receive Initial CYB003 Dose

First dose is administered as first-ever novel psilocybin analog enters clinical developmentCybin believes CYB003 has potential to successfully address the challenges and limitations of oral psilocybinThe high level of participant interest in the study indicates a significant unmet need for alternative treatment options for major depressive disorder (“MDD”) Cybin (NEO: CYBN) (NYSE American: CYBN) has reached a milestone in its mission to create safe and effective therapeutics. The company is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and the first-ever novel psilocybin analog to enter clinical development. Late last month, the first two trial participants were dosed…

Continue Reading

TuesdaySep 20, 2022 11:15 am

QSAM Biosciences Inc. (QSAM) Working to Halt, Regress Bone Tumors in Children Through Therapeutic Radiopharmaceuticals

Overall incidence of childhood cancer is on the increase, averaging 0.8% increase per year since 1975, reports leading advocacy organizationQSAM developing therapeutic radiopharmaceuticals as safer, more efficacious alternatives to address unmet medical needs, underserved patient populationsCompany creating pipeline of novel radiotherapeutics to serve multiple indications with its lead product, CycloSam With the overall incidence of childhood cancer on the rise, the work of QSAM Biosciences (OTCQB: QSAM) is becoming increasingly important. QSAM Biosciences is a clinical-stage biotechnology company focused on developing and bringing to market targeted therapeutic radiopharmaceuticals and advancing the fight against cancer, including the underserved pediatric population. “The…

Continue Reading

MondaySep 19, 2022 12:00 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Participates in H.C. Wainwright 24th Annual Global Investment Conference, Presenting Key Investor Highlights on Novel Anthracycline Berubicin for GBM Treatment

Glioblastoma multiforme (“GBM”) is one of the most aggressive, deadly, and treatment-resistant forms of cancer within the brain, with an average life expectancy of 12-18 months and more than 50,000 new cases each yearThe current standard of care for GBM is ineffective for approximately 60% of patientsInitial Phase 1 trial information for Berubicin (approximately 14 years ago) resulted in one patient surviving cancer-free to present and two experiencing significant tumor reduction of up to 80% CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for brain tumors, recently participated in the H.C. Wainwright…

Continue Reading

FridaySep 16, 2022 11:30 am

Trucking Supply Chain Tech Innovator Freight Technologies Inc. (NASDAQ: FRGT) Reports New Revenue Growth on B2B Marketplace Solution

Cross-border shipping solutions developer Freight Technologies Inc. is a B2B marketplace builder focused on providing the commercial trucking industry with transparent and efficient automation to simplify necessary communications, coordination and paperworkFreight Technologies, also known as Fr8Tech, upgraded its brand and ticker symbol earlier this year following its reverse merger with Hudson Capital Inc.Amid the upgrade, the company is reporting new record quarterly revenue that grew by 60 percent over the previous quarter and 45 percent YOYThe company expects improving market conditions as the nation continues to rebound from COVID’s economic effects to drive long-term growth At the height of the…

Continue Reading

FridaySep 16, 2022 9:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX), Growing its Market Share, One Patent at a Time

Lexaria’s development of its patented DehydraTECH(TM) technology since 2014 has yielded 27 patents in Australia, the United States, the European Union, Japan, India and Mexico with approximately 50 additional patents pending around the worldIts latest patent, granted in Mexico, applies a range of active ingredients, including but not limited to non-psychoactive cannabinoids and NSAIDs in a variety of ready-to-drink consumer retail beverage productsLexaria remains committed to advancing its research and expanding the indications and efficacy of its DehydraTECH technology, as it looks to benefit from the CBD industry, projected to be valued at $111.8 billion by 2030, and the cardiovascular…

Continue Reading

Contact us: (512) 354-7000